REMEDIUM
Timeline
41 events since 1993Board
Capital
Filings
Financial
End
Address
1995200020052010201520202025
2019
Merger: absorbed by MVT INVESTDissolution of the company · Dissolved without liquidation · MVT INVEST holds all the shares · General meeting of 13-06-20195 points ▸
- General meeting of 13-06-2019
- Merger by absorption
- MVT INVEST holds all the shares
- The operation takes effect in the accounts on 01-01-2019
- Power of attorney granted to
- The deed holds 3 more points.
Annual accounts 2018 filed PDFfull format · 29 days before the deadline
- Merger by absorption
- The operation takes effect in the accounts on 01-01-2019
- Board meeting of 21-03-2019
- The deed holds 5 more points.
2018
Highest result from 2006 to 2018 net €425,229 ▲1,755% The operating result of €602,544 and the net result of €425,229 are both a record.
Liquidity triples current ratio 3.78 The current ratio rises from 1.24 to 3.78. Short-term debt falls from €290,269 to €182,050.
Equity above €500,000 equity €711,342 ▲149% Equity rises from €286,113 to €711,342.
Registered office moved from Brussels to AnderlechtThe registered office moved from Chaussée d'Alsemberg, 718-1180 Bruxelles to Square Marie Curie 30, 1070 Anderlecht · (managing director) and MVT Invest SA (director) resign · (chair), (managing director), and (statutory auditor) appointed · General meeting of 28-05-201815 points ▸
- General meeting of 28-05-2018
- resigns as director
- MVT Invest SA resigns as director
- resigns as managing director
- Discharge granted to
- Discharge granted to MVT Invest SA
- appointed as director
- appointed as director
- appointed as director
- appointed as statutory auditor
- acts as permanent representative
- Board meeting of 28-05-2018
- The registered office moved to Square Marie Curie 30, 1070 Anderlecht
- appointed as chair
- appointed as managing director
Annual accounts 2017 filed PDFfull format · 35 days before the deadline
2017
Annual accounts 2016 filed PDFfull format · 3 days before the deadline
2016
Annual accounts 2015 filed PDFfull format · 29 days late
2015
Annual accounts 2014 filed PDFfull format · 18 days late
2 directors reappointed and MVT INVEST · acts as permanent representative · General meeting of 20-04-20154 points ▸
- General meeting of 20-04-2015
- reappointed as director
- MVT INVEST reappointed as director
- acts as permanent representative
2014
Annual accounts 2013 filed PDFfull format · 5 days late
2013
Annual accounts 2012 filed PDFfull format · 8 days before the deadline
Merger: IMVALCO takes over REMEDIUMCompany renamed from IMVALCO to REMEDIUM · “nouveau texte article 3” (deed in French) · holds 1 share · General meeting of 17-06-201311 points ▸
- General meeting of 17-06-2013
- holds 1 share
- MVT INVEST holds 1,249 shares
- The company holds all the shares of REMEDIUM
- Merger by absorption
- The capital is divided into 1,250 shares
- The operation takes effect in the accounts on 01-01-2013
- Power of attorney granted to
- Name change, REMEDIUM
- Purpose change, “nouveau texte article 3” (deed in French)
- Power of attorney granted to
- The deed holds 14 more points.
Merger proposal: IMVALCO takes over REMEDIUM1 point ▸
- The operation takes effect in the accounts on 01-01-2013
- The deed holds 3 more points.
2012
Equity above €200,000 equity €206,727 ▲6.8% With a profit in every financial year since 2006, equity grows to €206,727.
- General meeting of 04-06-2010
- MVT INVEST reappointed as director
Annual accounts 2011 filed PDFfull format · 46 days before the deadline
Publication in the Belgian Official Gazette PDFCapital €62,000, annual accounts 2012
2011
Annual accounts 2010 filed PDFfull format · 13 days before the deadline
2010
Annual accounts 2009 filed PDFfull format · 12 days before the deadline
2009
Annual accounts 2008 filed PDFfull format · 9 days before the deadline
2008
Weakest financial year net €5,381 ▼72.6% The net result drops to €5,381, the lowest from 2006 to 2018.
(managing director) and (director) reappointedGeneral meeting of 06-06-20083 points ▸
- General meeting of 06-06-2008
- reappointed as managing director
- reappointed as director
Annual accounts 2007 filed PDFfull format · 31 days before the deadline
2007
Equity above €150,000 equity €163,395 ▲13.7% With a profit in every financial year since 2006, equity grows to €163,395.
Annual accounts 2006 filed PDFfull format · 27 days before the deadline
2006
Annual accounts 2005 filed PDFfull format
2005
Annual accounts 2004 filed PDFfull format
2004
Annual accounts 2003 filed PDFfull format
2003
Annual accounts 2002 filed PDFfull format
2002
Annual accounts 2001 filed PDFfull format
2001
Annual accounts 2000 filed PDFfull format
2000
Annual accounts 1999 filed PDFfull format
1999
Annual accounts 1998 filed PDFfull format
1998
Annual accounts 1997 filed NBBfull format
1997
Annual accounts 1996 filed NBBfull format
1996
Annual accounts 1995 filed NBBfull format
1995
Annual accounts 1994 filed NBBfull format
1993
Incorporation 28 publications in the Belgian Official Gazette, the last on 11-07-2019
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
REMEDIUM was merged into REMEDIUM in 2013.1 In 2018 the registered office moved to Anderlecht.2 In 2019 the company was absorbed by merger into MVT INVEST.3